Page 3 - Column Group News Today

/PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

San Diego-based biotech developer Tr1X, a company developing therapies to treat autoimmune disease, announced this morning that it has raised $75M in a Series A financing round. The funding was led by The Col

Startup TrX1 develops cell therapies that function like a particular type of regulatory T cell, or Treg, whose role includes dampening inflammation and inducing long-term tolerance. Based on research from Stanford, TrX1’s lead program is a potential therapy for preventing graft-versus-host disease.

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 4,800 shares, a decline of 59.7% from the December 15th total of 11,900 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average […]

NGM Biopharmaceuticals, Inc. has recently received a non-binding expression of interest from The Column Group, LP and its affiliated investment funds and individuals. This EOI outlines their...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

BioPharma

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!